Billerica, Massachusetts, June 1, 2015 – EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today announced the launch of its Cellvento CellventoTM CHO platform of cell culture media and companion feed formulations for batch, fed-batch and perfusion applications. Available in liquid and powder form, the chemically defined, non-animal-origin media deliver superior cell growth and productivity for various CHO cell types used in biopharmaceutical development and manufacturing.
The CellventoTM CHO platform includes cell line and process-specific media and feed compositions, allowing selection of the optimal media formulation for a given application. The range of products also offers customers the flexibility to choose the most suitable product to achieve the best possible performance results for their specific cell line.
The platform provides a variety of formulations designed to meet the needs of CHO-S, CHO-DHFR negative and CHO-K1 suspension cell types. All formulations offer excellent powder homogeneity and consistency, resulting in strong lot-to-lot reproducibility. The media are supported by comprehensive regulatory information on their manufacture, characterization and control.
“Biopharmaceutical manufacturers require cell culture media that will deliver the most robust product yield, quality and consistency,” said Andrew Bulpin, executive vice president of EMD Millipore, Process Solutions Business Area. “The CellventoTM CHO platform offers a variety of formulations, all backed by EMD Millipore’s strong chemical, raw material and regulatory expertise. This range of options ensures customers have the flexibility to select the best media for their specific process, optimizing their production and ultimately accelerating time to market.”
The CellventoTM CHO platform includes the following media:
|Medium||Cell line||Use and application|
|CellventoTM CHO-100||CHO-S||Growth medium for batch and perfusion|
|CellventoTM CHO-110||CHO-DHFR negative||Growth medium for batch and perfusion|
|CellventoTM CHO-200||CHO-S||Production medium for fed-batch|
|CellventoTM CHO-210||CHO-DHFR negative||Production medium for fed-batch|
|CellventoTM CHO-220||CHO-K1||Production medium for fed-batch|
The production media all have companion feed formulations to extend the cell production phase and maximize yields.
For more information about the CellventoTM CHO platform, please visit www.emdmillipore.com/cellvento.
About EMD Millipore
EMD Millipore is the U.S. Life Science subsidiary of Merck KGaA, Darmstadt, Germany. As part of the global Life Science business of Merck KGaA, Darmstadt, Germany, EMD Millipore offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the life science tools industry, the Life Science business of Merck KGaA, Darmstadt, Germany, serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the global business has around 10,000 employees, operations in 66 countries and 2014 revenues of €2.7 billion.
For more information, please visit www.emdmillipore.com.